Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRX-917 repeat-dose proof-of-concept panic challenge study in healthy volunteers
NL-OMON51369Withdrawn
- Sponsor
- GABA Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Deuterated etifoxine in anxiety disorder and panic disorder, sponsored by GABA Therapeutics. Planned start Dec 2022; status: withdrawn.
02
Drugs
Deuterated etifoxine
03
Conditions
anxiety disorderpanic disorder
Beyond the preview
Go deeper on NL-OMON51369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51369.